{
  "company": {
    "name": "Flamingo Therapeutics",
    "website": "https://flamingotx.com/",
    "record": "https://startuphistory.org/c/flamingotx.com"
  },
  "status": null,
  "history_since": "2021-09-10T12:28:32.000Z",
  "baseline": {
    "snapshot_id": "8cf47ccc4bca893c41382c0ed8f02b7c080591d516869e3848b086c24e3b1c4d",
    "observed_at": "2021-09-10T12:28:32.000Z",
    "headline": null,
    "description": "Our State-of-the Art Chemistries Drive Innovation. At Flamingo, we understand drug development - and more importantly - we understand RNA therapeutic drug development. We know that robust and novel ba",
    "evidence": "https://web.archive.org/web/20210910122832/https://flamingotx.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 0,
  "last_checked": null,
  "live_status": "offline",
  "messaging": [
    {
      "quote_observed_at": "2025-12-07T22:23:14.000Z",
      "variants": [
        {
          "headline": "Flamingo Therapeutics - Pioneering RNA-targeted Therapies for Oncology",
          "subhead": "We understand drug development – and more importantly – we understand RNA therapeutic drug development. We know that robust and novel backbone chemistry is paramount when developing any RNA therapeuti",
          "observed_at": "2022-01-22T05:56:57.000Z",
          "evidence": "https://web.archive.org/web/20220122055657/https://flamingotx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Flamingo Therapeutics - Pioneering RNA-targeted Therapies for Oncology",
          "subhead": "We understand drug development – and more importantly – we understand RNA therapeutic drug development. We know that robust and novel backbone chemistry is paramount when developing any RNA therapeuti",
          "observed_at": "2022-07-03T20:45:19.000Z",
          "evidence": "https://web.archive.org/web/20220703204519/https://flamingotx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Flamingo Therapeutics - Pioneering RNA-targeted Therapies for Oncology",
          "subhead": "We understand drug development – and more importantly – we understand RNA therapeutic drug development. We know that robust and novel backbone chemistry is paramount when developing any RNA therapeuti",
          "observed_at": "2023-01-28T20:07:42.000Z",
          "evidence": "https://web.archive.org/web/20230128200742/https://flamingotx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Flamingo Therapeutics - Pioneering RNA-targeted Therapies for Oncology",
          "subhead": "We understand drug development – and more importantly – we understand RNA therapeutic drug development. We know that robust and novel backbone chemistry is paramount when developing any RNA therapeuti",
          "observed_at": "2023-09-25T07:19:31.000Z",
          "evidence": "https://web.archive.org/web/20230925071931/https://flamingotx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Flamingo Therapeutics - Pioneering RNA-targeted Therapies for Oncology",
          "subhead": "We understand drug development – and more importantly – we understand RNA therapeutic drug development. We know that robust and novel backbone chemistry is paramount when developing any RNA therapeuti",
          "observed_at": "2024-02-03T02:44:51.000Z",
          "evidence": "https://web.archive.org/web/20240203024451/https://flamingotx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Flamingo Therapeutics - Pioneering RNA-targeted Therapies for Oncology",
          "subhead": "We understand drug development – and more importantly – we understand RNA therapeutic drug development. We know that robust and novel backbone chemistry is paramount when developing any RNA therapeuti",
          "observed_at": "2024-07-15T05:32:28.000Z",
          "evidence": "https://web.archive.org/web/20240715053228/https://flamingotx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Flamingo Therapeutics - Pioneering RNA-targeted Therapies for Oncology",
          "subhead": "We understand drug development – and more importantly – we understand RNA therapeutic drug development. We know that robust and novel backbone chemistry is paramount when developing any RNA therapeuti",
          "observed_at": "2025-01-08T16:35:51.000Z",
          "evidence": "https://web.archive.org/web/20250108163551/https://flamingotx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Flamingo Therapeutics - Pioneering RNA-targeted Therapies for Oncology",
          "subhead": "We understand drug development – and more importantly – we understand RNA therapeutic drug development. We know that robust and novel backbone chemistry is paramount when developing any RNA therapeuti",
          "observed_at": "2025-07-10T03:38:10.000Z",
          "evidence": "https://web.archive.org/web/20250710033810/https://flamingotx.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Flamingo Therapeutics - Pioneering RNA-targeted Therapies for Oncology",
          "subhead": "We understand drug development – and more importantly – we understand RNA therapeutic drug development. We know that robust and novel backbone chemistry is paramount when developing any RNA therapeuti",
          "observed_at": "2025-12-07T22:23:14.000Z",
          "evidence": "https://web.archive.org/web/20251207222314/https://flamingotx.com",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Flamingo Therapeutics - Pioneering RNA-targeted Therapies for Oncology",
      "subhead": "We understand drug development – and more importantly – we understand RNA therapeutic drug development. We know that robust and novel backbone chemistry is paramount when developing any RNA therapeuti",
      "from": "2022-01-22T05:56:57.000Z",
      "to": "2025-12-07T22:23:14.000Z",
      "captures": 9,
      "evidence": "https://web.archive.org/web/20251207222314/https://flamingotx.com",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2022-01-22T05:56:57.000Z",
          "to": "2025-12-07T22:23:14.000Z"
        }
      },
      "current": true
    }
  ],
  "changes": [],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Flamingo Therapeutics” company record, https://startuphistory.org/c/flamingotx.com"
}